Ocugen Is Presenting Grants Under Nasdaq Listing Rule 5635(c)(4)

First American News LLC, Raleigh NC: Ocugen is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Today the company is presenting Grants Under Nasdaq Listing Rule 5635(c)(4).

The company further announced the Compensation Committee of the Board of Directors of Ocugen (OCGN) approved the grant of stock options to purchase an aggregate of 787,268 shares of its common stock and restricted stock units (RSUs) covering an aggregate of 217,681 shares of common stock to three newly hired team members.

The stock options and RSUs were granted on January 10, 2022, and January 17, 2022, as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4). 687,872 of the stock options and 190,198 of the RSUs were issued on January 10, 2022, to a new member of the management team, whose appointment will be announced at a later date.

Subscribe 5-Years to Bloomberg News for $49

The stock options have a ten-year term and exercise prices of $4.32 and $4.25 per share, which were the closing prices of Ocugen’s common stock on January 10 and January 14, respectively. The stock options and RSUs vest in equal annual installments over a three-year period starting on the one-year anniversary of the grant date, subject to the applicable new employee’s continued service with Ocugen through the applicable vesting dates. The stock options and RSUs were granted outside of Ocugen’s 2019 Equity Incentive Plan. Read more at WSJ Renewal.

About Ocugen, Inc.
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug — “one to many,” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. and Canadian markets.

See Our Full Digital News Library